Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 291

Sort by

Sort Order Select

Journal Articles

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Blood (2023) 142 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2023-190473

Published: 2023

Journal Articles

Young and Distinct: Clinical Characteristics and Outcomes of Patients 50 or Younger with Multiple Myeloma

Andrea Tufano-Sugarman, Shahidul Islam, Faith E. Davies, Gareth J. Morgan, David Kaminetzky, Marc Braunstein

Blood (2023) 142 (Supplement 1): 6684.

https://doi.org/10.1182/blood-2023-182954

Published: 2023

Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies

Blood (2023) 142 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2023-181304

Published: 2023

Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 874.

https://doi.org/10.1182/blood-2023-186802

Published: 2023

Journal Articles

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Nathan Beals, Craig Ramirez, Andy Hauser, Faith E. Davies, Dafna Bar-Sagi, Gareth J. Morgan

Blood (2023) 142 (Supplement 1): 54.

https://doi.org/10.1182/blood-2023-186114

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Molly Reed, David Allan Cairns, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Roger Owen, Kevin Boyd, Gordon Cook, Gareth J. Morgan, Graham Jackson, Mark Drayson, John R Jones

Blood (2023) 142 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2023-181939

Published: 2023

Journal Articles

The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma

Yubao Wang, Sanxiong Liu, Hussein Ghamlouch, Eileen Boyle, Faith E. Davies, Gareth J. Morgan

Blood (2023) 142 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2023-189012

Published: 2023

Journal Articles

Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development

Hussein Ghamlouch, Dylan Gagler, Patrick Blaney, Eileen Boyle, Yubao Wang, Liming Hou, Ola Landgren, Francesco Maura, Aristotelis Tsirigos, Gareth J. Morgan, Faith E. Davies

Blood (2023) 142 (Supplement 1): 332.

https://doi.org/10.1182/blood-2023-182968

Published: 2023

Journal Articles

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Blood (2023) 142 (Supplement 1): 3764.

https://doi.org/10.1182/blood-2023-190882

Published: 2023

Journal Articles

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Aikaterini Panopoulou, David A. Cairns, Amy Holroyd, Isabel Nichols, Nikita Cray, Charlotte Pawlyn, Gordon Cook, Mark Drayson, Kevin Boyd, Faith E. Davies, Matthew Jenner, Gareth J. Morgan, Roger Owen, Richard Houlston, Graham Jackson, Martin F. Kaiser

Blood (2023) 141 (14): 1666–1674.

https://doi.org/10.1182/blood.2022018339

Published: 2023

Includes: Supplemental data

Journal Articles

Tracking the Earliest Genomic Events in Multiple Myeloma Life-History

Blood (2022) 140 (Supplement 1): 1553–1555.

https://doi.org/10.1182/blood-2022-164742

Published: 2022

Journal Articles

The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma

Benjamin Dimbleby, Tatiana Zhelezniakova, Alex G Richter, Charlotte Pawlyn, John R Jones, Matthew W Jenner, David Cairns, Tom Menzies, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan, Mark T Drayson

Blood (2022) 140 (Supplement 1): 4299–4300.

https://doi.org/10.1182/blood-2022-169774

Published: 2022

Journal Articles

The Mutagenic Impact of Radiotherapy in Multiple Myeloma

Benjamin Diamond, Alexandra M Poos, Bachisio Ziccheddu, Kylee H Maclachlan, Yanming Zhang, Saad Usmani, Eileen M Boyle, Faith E Davies, Gareth J. Morgan, Ola Landgren, Marc S Raab, Francesco Maura, Niels Weinhold

Blood (2022) 140 (Supplement 1): 7125–7126.

https://doi.org/10.1182/blood-2022-166531

Published: 2022

Journal Articles

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Blood (2022) 140 (Supplement 1): 1137–1139.

https://doi.org/10.1182/blood-2022-160308

Published: 2022

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

Advanced Practice Providers (APPs) in Hematology: Work Practices, Interactions with Physicians, and Opportunities for Collaboration within the American Society of Hematology (ASH)

Leah E Masselink, Clese E Erikson, Gina Moses, Faith E. Davies, Azam Farooqui, Peter A. Kouides, Srikanth Nagalla, Ariela L. Marshall

Blood (2022) 140 (Supplement 1): 1617–1618.

https://doi.org/10.1182/blood-2022-157185

Published: 2022

Journal Articles

Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma

Blood (2022) 140 (Supplement 1): 4253–4254.

https://doi.org/10.1182/blood-2022-165467

Published: 2022

Journal Articles

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

John R Jones, David Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Matthew W Jenner, Martin F. Kaiser, Rebecca Mottram, Mark T Drayson, Walter Martin Gregory, Roger G Owen, Kevin Boyd, Gordon Cook, Graham Jackson, Gareth J. Morgan

Blood (2022) 140 (Supplement 1): 1823–1825.

https://doi.org/10.1182/blood-2022-168723

Published: 2022

Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Blood (2022) 140 (Supplement 1): 430–432.

https://doi.org/10.1182/blood-2022-167390

Published: 2022

NARROW

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Young and Distinct: Clinical Characteristics and Outcomes of Patients 50 or Younger with Multiple Myeloma

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma

Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Tracking the Earliest Genomic Events in Multiple Myeloma Life-History

The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma

The Mutagenic Impact of Radiotherapy in Multiple Myeloma

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Advanced Practice Providers (APPs) in Hematology: Work Practices, Interactions with Physicians, and Opportunities for Collaboration within the American Society of Hematology (ASH)

Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only